IMVT-1402 bets on FcRn blockade across RA, MG, and Graves disease after batoclimab's Phase 3 TED failure resets the entire investment case

Bull

A positive outcome would be statistically significant ACR20/50/70 responses in the blinded randomized period that confirm the open-label Week 16 signal (ACR20 ~73%, ACR50 ~55%), demonstrating durable IgG reduction translates into meaningful clinical benefit in patients who have failed two or more advanced therapies including JAK inhibitors and anti-TNF agents. This would validate FcRn blockade as a mechanistically differentiated approach in D2T RA, support a registrational package for the first indication, and de-risk the broader multi-indication platform thesis — restoring investor confidence following the TED setbacks.

Bear

The most likely failure mode is an adequate blinded placebo response rate eroding the treatment difference, as open-label ACR rates are historically inflated relative to placebo-controlled results in RA trials. A second risk is that IgG reduction, while robust, does not translate to ACR response superiority over placebo in a population whose disease is driven by mechanisms beyond circulating antibody titers — particularly in patients with prior JAK inhibitor failure where cellular and cytokine-driven pathways may predominate over autoantibody pathology.